Iron Overload, Oxidative Stress, and Somatic Mutations in MDS: What Is the Association?

被引:0
作者
Leitch, Heather A. [1 ,2 ]
机构
[1] St Pauls Hosp, Hematol, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC, Canada
关键词
IOL; iron overload; MDS; oxidative stress; reactive oxygen species; ROS; somatic mutations; TRANSFUSION-DEPENDENT PATIENTS; LABILE PLASMA IRON; HEALTH-ORGANIZATION CLASSIFICATION; RISK MYELODYSPLASTIC SYNDROMES; PROTEIN-TYROSINE PHOSPHATASES; PROGNOSTIC SCORING SYSTEM; TRANSFERRIN-BOUND IRON; CHELATION-THERAPY; REACTIVE OXYGEN; LEUKEMIA-CELLS;
D O I
10.1111/ejh.14385
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionIron overload (IOL) accumulates in myelodysplastic syndromes (MDS) from expanded erythropoiesis and transfusions. Somatic mutations (SM) are frequent in MDS and stratify patient risk. MDS treatments reversing or limiting transfusion dependence are limited.MethodsThe literature was reviewed on how IOL and oxidative stress interact with specific SM in MDS to influence cellular physiology. PubMed searches included keywords of each specific mutation combined with iron, oxidative stress, and reactive oxygens species (ROS). Papers relevant to hematopoietic stem/progenitor cells, the bone marrow microenvironment, MDS, AML or other myeloid disorders were preferred. Included were the most frequent SM in MDS, SM of the International Prognostic Scoring System-Molecular (IPSS-M), of familial predisposing conditions and the CMML PSS-molecular.ResultsAbout 31 SM plus four familial conditions were searched. Discussed are the frequency of each SM, whether function is gained or lost, early or late SM status, a function of the unmutated gene, and function considering iron and oxidative stress.DiscussionGiven limited effective MDS therapies, considering how IOL and ROS interact with SM to influence cellular physiology in the hematopoietic system, increasing bone marrow failure progression or malignant transformation may be of benefit and support optimization of measures to reduce IOL or neutralize ROS.
引用
收藏
页数:23
相关论文
共 177 条
[1]   Prognostic impact of RAS mutations in patients with myelodysplastic syndrome [J].
Al-Kali, Aref ;
Quintas-Cardama, Alfonso ;
Luthra, Raja ;
Bueso-Ramos, Carlos ;
Pierce, Sherry ;
Kadia, Tapan ;
Borthakur, Gautam ;
Estrov, Zeev ;
Jabbour, Elias ;
Faderl, Stefan ;
Ravandi, Farhad ;
Cortes, Jorges ;
Tefferi, Ayalew ;
Kantarjian, Hagop ;
Garcia-Manero, Guillermo .
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) :365-369
[2]   Two different "tales" of ATG7: Clinical relevance to myelodysplastic syndromes [J].
Ali, Abdullah M. ;
Raza, Azra .
MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (05)
[3]   Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 [J].
Ambaglio, Ilaria ;
Malcovati, Luca ;
Papaemmanuil, Elli ;
Laarakkers, Coby M. ;
Della Porta, Matteo G. ;
Galli, Anna ;
Da Via, Matteo C. ;
Bono, Elisa ;
Ubezio, Marta ;
Travaglino, Erica ;
Albertini, Riccardo ;
Campbell, Peter J. ;
Swinkels, Dorine W. ;
Cazzola, Mario .
HAEMATOLOGICA, 2013, 98 (03) :420-423
[4]   Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial [J].
Angelucci, Emanuele ;
Li, Junmin ;
Greenberg, Peter ;
Wu, Depei ;
Hou, Ming ;
Montano Figueroa, Efreen Horacio ;
Guadalupe Rodriguez, Maria ;
Dong, Xunwei ;
Ghosh, Jagannath ;
Izquierdo, Miguel ;
Garcia-Manero, Guillermo .
ANNALS OF INTERNAL MEDICINE, 2020, 172 (08) :513-+
[5]   Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial) [J].
Angelucci, Emanuele ;
Santini, Valeria ;
Di Tucci, Anna Angela ;
Quaresmini, Giulia ;
Finelli, Carlo ;
Volpe, Antonio ;
Quarta, Giovanni ;
Rivellini, Flavia ;
Sanpaolo, Grazia ;
Cilloni, Daniela ;
Salvi, Flavia ;
Caocci, Giovanni ;
Molteni, Alfredo ;
Vallisa, Daniele ;
Voso, Maria Teresa ;
Fenu, Susanna ;
Borin, Lorenza ;
Latte, Giancarlo ;
Alimena, Giuliana ;
Storti, Sergio ;
Piciocchi, Alfonso ;
Fazi, Paola ;
Vignetti, Marco ;
Tura, Sante .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (06) :527-536
[6]   International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert P. ;
Borowitz, Michael J. ;
Calvo, Katherine R. ;
Kvasnicka, Hans-Michael ;
Wang, Sa A. ;
Bagg, Adam ;
Barbui, Tiziano ;
Branford, Susan ;
Bueso-Ramos, Carlos E. ;
Cortes, Jorge E. ;
Dal Cin, Paola ;
DiNardo, Courtney D. ;
Dombret, Herve ;
Duncavage, Eric J. ;
Ebert, Benjamin L. ;
Estey, Elihu H. ;
Facchetti, Fabio ;
Foucar, Kathryn ;
Gangat, Naseema ;
Gianelli, Umberto ;
Godley, Lucy A. ;
Gokbuget, Nicola ;
Gotlib, Jason ;
Hellstrom-Lindberg, Eva ;
Hobbs, Gabriela S. ;
Hoffman, Ronald ;
Jabbour, Elias J. ;
Kiladjian, Jean-Jacques ;
Larson, Richard A. ;
Le Beau, Michelle M. ;
Loh, Mignon L. -C. ;
Lowenberg, Bob ;
Macintyre, Elizabeth ;
Malcovati, Luca ;
Mullighan, Charles G. ;
Niemeyer, Charlotte ;
Odenike, Olatoyosi M. ;
Ogawa, Seishi ;
Orfao, Alberto ;
Papaemmanuil, Elli ;
Passamonti, Francesco ;
Porkka, Kimmo ;
Pui, Ching-Hon ;
Radich, Jerald P. ;
Reiter, Andreas ;
Rozman, Maria ;
Rudelius, Martina ;
Savona, Michael R. .
BLOOD, 2022, 140 (11) :1200-1228
[7]   Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach COMMENT [J].
Arber, Daniel A. ;
Hasserjian, Robert P. ;
Orazi, Attilio ;
Mathews, Vikram ;
Roberts, Andrew W. ;
Schiffer, Charles A. ;
Roug, Anne Stidsholt ;
Cazzola, Mario ;
Doehner, Hartmut ;
Tefferi, Ayalew .
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) :514-518
[8]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[9]   A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612 [J].
Assouline, Sarit ;
Michaelis, Laura C. ;
Othus, Megan ;
Hay, Annette E. ;
Walter, Roland B. ;
Jacoby, Meagan A. ;
Schroeder, Mark A. ;
Uy, Geoffrey L. ;
Law, Lisa Y. ;
Cheema, Faisal ;
Sweet, Kendra L. ;
Asch, Adam S. ;
Liu, Jijun ;
Moseley, Anna B. ;
Maher, Tracy ;
Kingsbury, Laura L. ;
Fang, Min ;
Radich, Jerald ;
Little, Richard F. ;
Erba, Harry P. .
LEUKEMIA & LYMPHOMA, 2023, 64 (02) :473-477
[10]   Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene STAG2 [J].
Bailey, Melanie L. ;
Tieu, David ;
Habsid, Andrea ;
Tong, Amy Hin Yan ;
Chan, Katherine ;
Moffat, Jason ;
Hieter, Philip .
LIFE SCIENCE ALLIANCE, 2021, 4 (11)